Global Humanized Liver Mice Model Market Overview
A lot of studies are underway to create novel humanized liver mouse models. Initially, liver mice models were created by implanting human liver cells or hepatic cancer cells into basic immune-deficient mice. The results, however, were inconsistent and unreliable. As a result, immune-deficient mice were developed, which spontaneously destroy the mice liver, allowing human liver cells to proliferate and replace it, resulting in stable humanized liver mice models. For example, a number of research projects are looking into using PPARalfa and AFC8-based Mice Model to develop humanized liver mice models. The hPXR/CAR/CYP3A4/ 2D6/2C9 mouse is a humanized liver mouse model with 33 mouse genes substituted with human genetic counterparts. Furthermore, as genetic technology advances, there is a greater possibility of producing new genetically modified humanized liver mouse models. CRISPR technology is one such example. The Global Humanized Liver Mice Model Market accounted for US$ 78.64 million in 2020 and is estimated to be US$ 133.72 million by 2030 and is anticipated to register a CAGR of 5.30%.
Global Humanized Liver Mice Model Market Dynamics
Increase in the number of FDA approvals for liver-based disease therapies will drive the growth of the Market
An increase in the number of FDA approvals for liver-based disease therapies has resulted in an increase in the number of research and development activities that require these models, such as the rising incidence of liver cirrhosis, technological advancement, and the development of new humanised liver mice. The growing number of drug approvals reflects the extent of research and toxicity studies, which includes pre-clinical investigations utilising illness animal models, such as humanised liver mice. For instance, despite the fact that the FDA has authorised a relatively small number of liver disease-related medications in recent years, the frequency of drug approvals is increasing. From 2011 to 2014, for example, just four hepatitis medicines were licenced. However, throughout the course of three years (2015–2017), there were around eight approvals for the same. However, the expansion of humanised liver mice models is projected to be hampered over the projection period due to the high cost of mice models, as well as high shipping costs and alternative availability. Regulatory hurdles, such as the patenting of mice, as well as other ethical issues, such as the implementation of 3Rs rules, are also predicted to stifle industry expansion.Cirrhosis of the liver is the final stage of a variety of chronic liver illnesses. Cirrhosis of the liver is becoming more common as the load of risk factors such as Hepatitis B virus (HBV), Hepatitis C virus (HCV), and liver cancer grows. In 2015, 257 million people worldwide were infected with chronic HBV. With an overall incidence of approximately 8%, Asia and Africa were the two continents with the highest endemic prevalence. According to Glococan 2018, liver cancer is the seventh most frequent type of cancer. Every year, around 841,080 people worldwide are diagnosed with liver cancer. With the rise in global frequency of liver cirrhosis, the number of research centred on treatment for such disorders is predicted to rise, propelling the humanised liver mice model market forward.
Global Humanized Liver Mice Model Market Segmentation
Source: Prophecy Market Insights |Disclaimer: Data is only a representation. Actual data may vary in the final report.
The Global Humanized Liver Mice Model Market is segmented based on model, application and region.
On the basis of Model, the Global Humanized Liver Mice Model Market is segmented into uPA-SCID, FRG KO Mice, TK-NOG Mice and Other Models. On the basis of Application, the Global Humanized Liver Mice Model Market is segmented into Pharmacokinetics Studies, In-vivo Liver Toxicity Testing, Drug Metabolism Studies and Others.
Regional Insights:
Source: Prophecy Market Insights
On region the Global Humanized Liver Mice Model Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. During the forecast period, North America is expected to dominate the market. North America is predicted to be the leading region in the worldwide humanized liver mice model market due to owing to the government's and business sector's support for research. Government financing and support for patenting genetically modified mice are two further reasons driving the growth of the humanized liver Mice Model industry in the region. Due to shifting government policies supporting the pharmaceutical and biopharmaceutical industries in the region, Asia Pacific, led by China, is likely to emerge as a profitable regional market for humanized liver mice models.
Report Scope:
|
Attribute |
Details |
|
Base year for estimation |
2020 |
|
Forecast period |
2020 – 2030 |
|
Market representation |
Revenue in USD Million & CAGR from 2020 – 2029 |
|
Market Segmentation |
By Model- uPA-SCID, FRG KO Mice, TK-NOG Mice and Other Models By Application– Pharmacokinetics Studies, In-vivo Liver Toxicity Testing, Drug Metabolism Studies and Others |
|
Regional scope |
North America - U.S., Canada Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, Rest of Latin America Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa |
|
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors, and trends |
Segments Covered in the Report:
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2019 to 2029. For the purpose of this study, has segmented the Global Humanized Liver Mice Model Market report based on model, application and region.
Global Humanized Liver Mice Model Market, By Region:
-
-
- North America
-
- U.S.
- Canada
-
- Europe
-
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
-
- Asia Pacific
-
- China
- India
- Japan
- South Korea
- Rest of Asia Pacific
-
- Latin America
-
- Brazil
- Mexico
- Rest of Latin America
-
- Middle East & Africa
-
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
-
- North America
-
Global Humanized Liver Mice Model Market Key Players
The key players operating in the humanized liver mice model market are The Jackson Laboratory, Crown Bioscience Inc. (JSR Life Science), Charles River Laboratories International, Inc., Taconic Biosciences, Inc., Ingenious Targeting Laboratory Inc., Trans Genic Inc., Ltd., GenOway, Creative Animodel, and Horizon Discovery Group plc
Global Humanized Liver Mice Model Market Company Profile
- The Jackson Laboratory
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Crown Bioscience Inc. (JSR Life Science)
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Charles River Laboratories International, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Taconic Biosciences, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Ingenious Targeting Laboratory Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Trans Genic Inc., Ltd.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- GenOway
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Horizon Discovery Group plc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
Global Humanized Liver Mice Model Market Table of Contents
- Research Objective and Assumption
- Preface
- Research Objectives
- Study Scope
- Years Considered for the study
- Assumptions
- Abbreviations
- Research Methodology
- Research data
- Primary Data
- Primary Interviews
- Primary Breakdown
- Key data from Primary Sources
- Key Thickness Insights
- Secondary Data
- Major Secondary Sources
- Secondary Sources
- Market Estimation
- Top-Down Approach
- Approach for estimating Market Share by Top-Down Analysis (Supply Side)
- Bottom-Up Approach
- Approach for estimating market share by Bottom-up Analysis (Demand Side)
- Market Breakdown and Data Triangulation
- Research Assumptions
- Market Purview
- Executive Summary
- Key Findings—Global Outlook for humanized liver mice model Strategies
- Key Questions this Study will Answer
- Market Snippet, By Model
- Market Snippet, By Application
- Opportunity Map Analysis
- Executive Summary—3 Big Predictions
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Market Trends
- DR Impact Analysis
- PEST Analysis
- Porter’s Five Forces Analysis
- Opportunity Orbit
- Market Investment Feasibility Index
- Macroeconomic Factor Analysis
- Market Dynamics
- Global Humanized Liver Mice Model Market, By Model, 2020 – 2030, (US$ Mn)
- Overview
- Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
- Y-o-Y Growth Analysis (%), 2020 – 2030
- Segment Trends
- uPA-SCID
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
- FRG KO Mice
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
- TK-NOG Mice
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
- Others
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
- Overview
- Global Humanized Liver Mice Model Market, By Application, 2020 – 2030, (US$ Mn)
- Overview
- Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
- Y-o-Y Growth Analysis (%), 2020 – 2030
- Segment Trends
- Pharmacokinetics Studies
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
- In-Vivo Liver Toxicity Testing
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
- Drug Metabolism Studies
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
- Others
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
- Overview
- Global Humanized Liver Mice Model Market, By Region, 2020 – 2030, (US$ Mn)
- Overview
- Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
- Y-o-Y Growth Analysis (%), 2020 – 2030
- Regional Trends
- North America
- Market Size and Forecast (US$ Mn), By Model, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Application, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
- U.S.
- Canada
- Europe
- Market Size and Forecast (US$ Mn), By Model, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Application, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
- UK
- France
- Germany
- Russia
- Italy
- Rest of Europe
- Asia Pacific
- Market Size and Forecast (US$ Mn), By Model, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Application, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
- India
- Japan
- South Korea
- China
- Rest of Asia Pacific
- Latin America
- Market Size and Forecast (US$ Mn), By Model, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Application, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- Market Size and Forecast (US$ Mn), By Model, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Application, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
- GCC
- Israel
- South Africa
- Rest of Middle East
- Overview
- Competitive Landscape
- Heat Map Analysis
- Market Presence and Specificity Analysis
- Company Profiles
- The Jackson Laboratory
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Crown Bioscience Inc. (JSR Life Science)
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Charles River Laboratories International, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Taconic Biosciences, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Ingenious Targeting Laboratory Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Trans Genic Inc., Ltd.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- GenOway
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Horizon Discovery Group plc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- The Last Word
- Future Impact
- About Us
- Contact
FAQs
Global Humanized Liver Mice Model Market is segmented based on model, application and region.
Increase in the number of FDA approvals for liver-based disease therapies is major factor driving the market.
During the forecast period, North America is expected to dominate the market.
The key players operating in the humanized liver mice model market are The Jackson Laboratory, Crown Bioscience Inc. (JSR Life Science), Charles River Laboratories International, Inc., Taconic Biosciences, Inc., Ingenious Targeting Laboratory Inc., Trans Genic Inc., Ltd., GenOway, Creative Animodel, and Horizon Discovery Group plc.